Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Respir Crit Care Med. 2013 Jul 15;188(2):179-86. doi: 10.1164/rccm.201211-2139OC.

Serum amyloid A promotes lung neutrophilia by increasing IL-17A levels in the mucosa and γδ T cells.

Author information

1
Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria, Australia.

Abstract

RATIONALE:

Neutrophilic inflammation is an important pathologic feature of chronic obstructive pulmonary disease (COPD) and infectious exacerbations of COPD. Serum amyloid A (SAA) promotes neutrophilic inflammation by its interaction with lung mucosal ALX/FPR2 receptors. However, little is known about how this endogenous mediator regulates IL-17A immunity.

OBJECTIVES:

To determine whether SAA causes neutrophilic inflammation by IL-17A-dependent mechanisms.

METHODS:

The relationship between SAA and neutrophils was investigated in lung sections from patients with COPD and a chronic mouse model of SAA exposure. A neutralizing antibody to IL-17A was used to block SAA responses in vivo, and a cell-sorting strategy was used to identify cellular sources.

MEASUREMENTS AND MAIN RESULTS:

SAA mRNA expression was positively associated with tissue neutrophils in COPD (P < 0.05). SAA predominately promoted expression of the TH17 polarizing cytokine IL-6, which was opposed by 15-epi-lipoxin A4, a counter-regulatory mediator, and ALX/FPR2 ligand. SAA-induced inflammation was markedly reduced by a neutralizing antibody to IL-17A in vivo. Cellular sources of IL-17A induced by SAA include CD4(+) T cells, γδ T cells, and an Epcam(+)CD45(-) population enriched for epithelial cells. SAA promotes expression of IL-17A in γδ T cells and this innate cell proportionally expressed higher levels of IL-17A transcript than CD4(+) T cells or epithelial cells.

CONCLUSIONS:

The SAA-IL-17A axis represents an important innate defense network that may underlie persistent neutrophilic airway inflammation in COPD and modulating the ALX/FPR2 receptor represents a novel approach to targeting aberrant IL-17A-mediated lung immunity.

PMID:
23627303
PMCID:
PMC3778755
DOI:
10.1164/rccm.201211-2139OC
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center